Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antihypertensive Efficacy of Triple Combination Perindopril/Indapamide Plus Amlodipine in High-Risk Hypertensives: Results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients)

Antihypertensive Efficacy of Triple Combination Perindopril/Indapamide Plus Amlodipine in... Am J Cardiovasc Drugs (2014) 14:137–145 DOI 10.1007/s40256-014-0067-2 OR IGINAL RESEARCH ARTIC L E Antihypertensive Efficacy of Triple Combination Perindopril/ Indapamide Plus Amlodipine in High-Risk Hypertensives: Results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients) ´ ´ ´ • KalmanToth on behalf of PIANIST Investigators Published online: 4 March 2014 Springer International Publishing Switzerland 2014 Abstract 147.4 ± 13.8/82.1 ± 11.9 to 122.6 ± 9.1/72.8 ± 7.4 mmHg Objective Our objective was to evaluate a triple-drug (p \ 0.0001). Ankle edema was infrequent (0.2 % of antihypertensive strategy for blood pressure control in patients). patients with difficult-to-treat hypertension. Conclusion Triple combination perindopril/indapamide/ Design The Perindopril-Indapamide plus AmlodipiNe in amlodipine was effectively and safely administered to a high rISk hyperTensive patients (PIANIST) trial was an large population of high- and very high-risk hypertensive observational, 4-month, open-label study. patients who had not reached target OBP values with Patients and interventions A total of 4,731 patients at previous treatment. high or very high cardiovascular risk with hypertension that was not properly controlled despite antihypertensive 1 Introduction therapy, and for whom study treatment (fixed-dose perin- dopril 10 mg/indapamide 2.5 mg ? amlodipine 5 or 10 mg) was consistent with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Antihypertensive Efficacy of Triple Combination Perindopril/Indapamide Plus Amlodipine in High-Risk Hypertensives: Results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients)

Loading next page...
 
/lp/springer-journals/antihypertensive-efficacy-of-triple-combination-perindopril-indapamide-wkJpfe2T9n

References (37)

Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-014-0067-2
pmid
24590580
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2014) 14:137–145 DOI 10.1007/s40256-014-0067-2 OR IGINAL RESEARCH ARTIC L E Antihypertensive Efficacy of Triple Combination Perindopril/ Indapamide Plus Amlodipine in High-Risk Hypertensives: Results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients) ´ ´ ´ • KalmanToth on behalf of PIANIST Investigators Published online: 4 March 2014 Springer International Publishing Switzerland 2014 Abstract 147.4 ± 13.8/82.1 ± 11.9 to 122.6 ± 9.1/72.8 ± 7.4 mmHg Objective Our objective was to evaluate a triple-drug (p \ 0.0001). Ankle edema was infrequent (0.2 % of antihypertensive strategy for blood pressure control in patients). patients with difficult-to-treat hypertension. Conclusion Triple combination perindopril/indapamide/ Design The Perindopril-Indapamide plus AmlodipiNe in amlodipine was effectively and safely administered to a high rISk hyperTensive patients (PIANIST) trial was an large population of high- and very high-risk hypertensive observational, 4-month, open-label study. patients who had not reached target OBP values with Patients and interventions A total of 4,731 patients at previous treatment. high or very high cardiovascular risk with hypertension that was not properly controlled despite antihypertensive 1 Introduction therapy, and for whom study treatment (fixed-dose perin- dopril 10 mg/indapamide 2.5 mg ? amlodipine 5 or 10 mg) was consistent with

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Mar 4, 2014

There are no references for this article.